Luyan Pharma Co.,Ltd. (SHE:002788)
China · Delayed Price · Currency is CNY 10.78
+0.34 (3.26%)
Sep 16, 2026, 3:04 PM CST
Luyan Pharma Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 4,188 | 8,229 | 3,190 | 3,493 | 3,236 | 3,034 | |
Market Cap Growth | 28.64% | 157.98% | -8.68% | 7.92% | 6.66% | -1.51% |
Enterprise Value | 8,833 | 12,798 | 7,860 | 8,216 | 7,721 | 7,052 |
Last Close Price | 10.78 | 20.45 | 7.61 | 8.02 | 7.19 | 6.50 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 15.62 | 29.30 | 9.23 | 9.61 | 9.38 | 9.92 |
Forward PE | - | 7.62 | 7.62 | 8.48 | 11.00 | 9.52 |
PS Ratio | 0.20 | 0.39 | 0.16 | 0.18 | 0.17 | 0.17 |
PB Ratio | 1.26 | 2.48 | 1.00 | 1.17 | 1.16 | 1.19 |
P/TBV Ratio | 1.57 | 3.09 | 1.27 | 1.52 | 1.44 | 1.49 |
P/FCF Ratio | 24.25 | 18.10 | 14.74 | 4.48 | - | - |
P/OCF Ratio | 11.12 | 11.95 | 5.52 | 2.67 | 13.94 | - |
PEG Ratio | - | 0.69 | 0.69 | 0.77 | 1.10 | 0.95 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.41 | 0.60 | 0.38 | 0.41 | 0.40 | 0.40 |
EV/EBITDA Ratio | 12.81 | 19.68 | 10.44 | 10.90 | 10.19 | 10.77 |
EV/EBIT Ratio | 16.05 | 22.17 | 11.49 | 11.82 | 10.99 | 11.75 |
EV/FCF Ratio | 51.15 | 28.15 | 36.33 | 10.54 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.59 | 1.47 | 1.55 | 1.63 | 1.82 | 1.75 |
Debt / EBITDA Ratio | 7.66 | 6.86 | 6.07 | 5.96 | 6.23 | 6.29 |
Debt / FCF Ratio | 30.57 | 10.76 | 22.88 | 6.23 | - | - |
Net Debt / Equity Ratio | 1.39 | 1.29 | 1.37 | 1.43 | 1.61 | 1.59 |
Net Debt / EBITDA Ratio | 7.36 | 6.57 | 5.81 | 5.64 | 5.92 | 6.22 |
Net Debt / FCF Ratio | 26.82 | 9.40 | 20.22 | 5.45 | -47.03 | -6.61 |
Asset Turnover | 1.66 | 1.63 | 1.68 | 1.68 | 1.79 | 1.89 |
Inventory Turnover | 7.25 | 6.70 | 6.97 | 7.16 | 7.44 | 7.52 |
Quick Ratio | 0.75 | 0.74 | 0.77 | 0.79 | 0.79 | 0.80 |
Current Ratio | 1.10 | 1.09 | 1.15 | 1.16 | 1.17 | 1.19 |
Return on Equity (ROE) | 8.12% | 8.56% | 11.27% | 12.64% | 13.12% | 12.17% |
Return on Assets (ROA) | 2.66% | 2.77% | 3.50% | 3.68% | 4.03% | 4.04% |
Return on Invested Capital (ROIC) | 5.03% | 5.64% | 7.10% | 7.44% | 7.61% | 7.35% |
Return on Capital Employed (ROCE) | 14.10% | 15.10% | 17.00% | 18.40% | 20.20% | 20.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.43% | 3.41% | 10.84% | 10.41% | 10.66% | 10.08% |
FCF Yield | 4.12% | 5.53% | 6.78% | 22.33% | -2.95% | -20.29% |
Dividend Yield | 3.26% | 1.71% | 4.60% | 3.74% | 4.17% | 4.61% |
Payout Ratio | 112.83% | 111.78% | 93.69% | 93.56% | 95.92% | 81.76% |
Buyback Yield / Dilution | -0.76% | -0.45% | -0.42% | 0.28% | -0.17% | -7.46% |
Total Shareholder Return | 2.50% | 1.26% | 4.18% | 4.02% | 4.01% | -2.84% |